Thromboprophylaxis in major abdominal surgery for cancer

European Journal of Surgical Oncology

Volumn 32, Issue 9, 2006, Pages 911-916

  Negus, J J ^a   Gardner, J J ^a   Tann, O ^a   Lewis, S ^a   Cohen, A T ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Cancer; Fondaparinux; Low molecular weight heparin; Surgery; Thromboembolism; Thromboprophylaxis

Indexed keywords

DALTEPARIN; ENOXAPARIN; FONDAPARINUX; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; PLACEBO;

ABDOMINAL CANCER; ABDOMINAL SURGERY; BLEEDING; CANCER SURVIVAL; CLINICAL TRIAL; DRUG EFFICACY; DRUG USE; HEALTH CARE; HEALTH CARE ORGANIZATION; HEPARIN INDUCED THROMBOCYTOPENIA; HIGH RISK POPULATION; HUMAN; INCIDENCE; INTERMITTENT PNEUMATIC COMPRESSION DEVICE; LONG TERM CARE; META ANALYSIS; PATHOGENESIS; PRIORITY JOURNAL; PROPHYLAXIS; PROTECTIVE CLOTHING; QUALITY OF LIFE; REVIEW; RISK FACTOR; RISK REDUCTION; SURGICAL TECHNIQUE; SYSTEMATIC REVIEW; THROMBOSIS; TREATMENT DURATION; VENOUS THROMBOEMBOLISM;

ABDOMEN; ANTICOAGULANTS; BANDAGES; COMBINED MODALITY THERAPY; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; NEOPLASMS; POLYSACCHARIDES; POSTOPERATIVE COMPLICATIONS; THROMBOEMBOLISM;

EID: 33750987356     PISSN: 07487983     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejso.2006.03.023     Document Type: Review

References (59)

1. Geerts W.H., Heit J.A., Clagett G.P., et al. Prevention of venous thromboembolism. Seventh ACCP Recommendations. Chest 126 (2004) 338S-400S
2. Heit J.A., Silverstein M.D., Mohr D.N., et al. Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study. Arch Intern Med 160 (2000) 809-815
3. Shen V.S., and Pollak E.W. Fatal pulmonary embolism in cancer patients: is heparin prophylaxis justified?. South Med J 73 (1980) 841-843
4. Levine M.N., and Lee A.Y. Treatment of venous thromboembolism in cancer patients. Semin Thromb Hemost 25 (1999) 45-49
5. THRIFT Consensus Group. Risk of and prophylaxis for venous thromboembolism in hospital patients. Thromboembolic Risk Factors (THRIFT) Consensus Group. BMJ 305 (1992) 567-574
6. Oster G., Tuden R.L., and Colditz G.A. Prevention of VTE after general surgery: cost-effectiveness analysis of alternative approaches to prophylaxis. Am J Med 82 (1987) 889-899
7. Clagett G.P., and Reisch J.S. Prevention of VTE in general surgical patients: results of a meta-analysis. Ann Surg 208 (1988) 227-240
8. Carson J.L., Kelley M.A., Duff A., Weg J.G., Fulkerson W.J., Palevsky H., et al. The clinical course of pulmonary embolism. N Engl J Med 326 (1992) 1240-1245
9. Sproul E. Carcinoma and venous thrombosis: the frequency of association of carcinoma in the body or tail of the pancreas with multiple venous thrombosis. Am J Cancer 34 (1938) 566-585
10. Collins R., Scrimgeour A., Yusef S., and Peto R. Reduction in fatal pulmonary embolism and venous thrombosis by perioperative administration of subcutaneous heparin: overview of results of randomised trials in general, orthopaedic and urologic surgery. N Engl J Med 318 (1988) 1162-1173
11. Nand S., Fisher S.G., Salgia R., and Fisher R.I. Hemostatic abnormalities in untreated cancer: incidence and correlation with thrombotic and hemorrhagic complications. J Clin Oncol 5 (1987) 1998-2003
12. Donati M.B., and Semeraro N. Cancer cell procoagulants and their pharmacological modulation. Haemostasis 14 (1984) 422-429
13. Reich R., Thompson E.W., Iwamoto Y., et al. Effects of inhibitors of plasminogen activator, serine proteinases, and collagenase IV on the invasion of basement membranes by metastatic cells. Cancer Res 48 (1988) 3307-3312
14. Lane D.A., Mannucci P.M., Bauer K.A., et al. Inherited thrombophilia: part 1. Thromb Haemost 76 (1996) 651-662
15. Gore J.M., Appelbaum J.S., Greene H.L., Dexter L., and Dalen J.E. Occult cancer in patients with acute pulmonary embolism. Ann Intern Med 96 (1982) 556-560
16. Griffin M.R., Stanson A.W., Brown M.L., et al. Deep venous thrombosis and pulmonary embolism. Risk of subsequent malignant neoplasms. Arch Intern Med 147 (1987) 907-911
17. Nordstrom M., Lindblad B., Anderson H., Bergqvist D., and Kjellstrom T. Deep venous thrombosis and occult malignancy: an epidemiological study. BMJ 308 (1994) 891-894
18. Baron J.A., Gridley G., Weiderpass E., Nyren O., and Linet M. Venous thromboembolism and cancer. Lancet 351 (1998) 1077-1080
19. Sorensen H.T., Mellemkjaer L., Steffensen F.H., Olsen J.H., and Nielsen G.L. The risk of a diagnosis of cancer after primary deep venous thrombosis or pulmonary embolism. N Engl J Med 338 (1998) 1169-1173
20. Prandoni P., Lensing A.W., Buller H.R., Cogo A., Prins M.J., Cattelan A.M., et al. Deep-vein thrombosis and the incidence of subsequent symptomatic cancer. N Engl J Med 327 (1992) 1128-1133
21. Goldberg R.J., Seneff M., Gore J.M., et al. Occult malignant neoplasm in patients with deep venous thrombosis. Arch Intern Med 147 (1987) 251-253
22. Dahl O.E., Aspelin T., Arnesen H., et al. Increased activation of coagulation and formation of late deep venous thrombosis following discontinuation of thromboprophylaxis after hip replacement surgery. Thromb Res 80 (1995) 299-306
23. Monreal M., Alastrue A., Rull M., et al. Upper extremity deep venous thrombosis in cancer patients with venous access devices - prophylaxis with a low molecular weight heparin (Fragmin). Thromb Haemost 75 (1996) 251-253
24. Kakkar V.V. The current status of low-dose heparin in the prophylaxis of thrombophlebitis and pulmonary embolism. World J Surg 2 (1978) 3-18
25. Bergqvist D. Postoperative thromboembolism: frequency, etiology, prophylaxis (1983), Springer-Verlag, Berlin
26. Zacharski L.R., and Ornstein D.L. Heparin and cancer. Thromb Haemost 80 (1998) 10-23
27. Hirsh J., Warkentin T.E., Raschke R., Granger C., Ohman E.M., and Dalen J.E. Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety. Chest 114 (1998) 489S-510S
28. Bergqvist D., Burmak U.S., Frisell J., et al. Low molecular weight heparin once daily compared with conventional low-dose heparin twice daily. A prospective double-blind multicentre trial on prevention of postoperative thrombosis. Br J Surg 73 (1986) 204-208
29. Kakkar V.V., Boeckl O., Boneu B., et al. Efficacy and safety of a low-molecular-weight heparin and standard unfractionated heparin for prophylaxis of postoperative venous thromboembolism: European multicenter trial. World J Surg 21 (1997) 2-8
30. Nurmohamed M.T., Rosendaal F.R., Buller H.R., et al. Low-molecular-weight heparin versus standard heparin in general and orthopaedic surgery: a meta-analysis. Lancet 340 (1992) 152-156
31. Kakkar V., Cohen A., Edmonson R., et al. Low molecular weight versus standard heparin for prevention of venous thromboembolism after major abdominal surgery. Lancet 341 (1993) 259-265
32. Kakkar V.V., and Murray W.J. Efficacy and safety of low-molecular-weight heparin (CY216) in preventing postoperative venous thrombo-embolism: a co-operative study. Br J Surg 72 (1985) 786-791
33. The European Fraxiparin Study (EFS) Group. Comparison of a low molecular weight heparin and unfractionated heparin for the prevention of deep vein thrombosis in patients undergoing abdominal surgery. The European Fraxiparin Study (EFS) Group. Br J Surg 75 (1988) 1058-1063
34. Bergqvist D., Matzsch T., Burmark U., et al. Low molecular weight heparin given the evening before surgery compared with conventional low-dose heparin in prevention of thrombosis. Br J Surg 75 (1988) 888-891
35. Speziale F., Verardi S., Taurino M., et al. Low molecular weight heparin prevention of post-operative deep vein thrombosis in vascular surgery. Pharmatherapeutica 5 (1988) 261-268
36. Liezorovicz A., Picolet H., Peyrieux J., and Boissel J. Prevention of perioperative deep vein thrombosis in general surgery: a multicentre double blind study comparing two doses of Logiparin and standard heparin. Br J Surg 78 (1991) 412-416
37. Caen J.P. A randomized double-blind study between a low molecular weight heparin Kabi 2165 and standard heparin in the prevention of deep vein thrombosis in general surgery. A French multicenter trial. Thromb Haemost 59 (1988) 216-220
38. Koppenhagen K., Adolf J., Matthes M., et al. Low molecular weight heparin and prevention of postoperative thrombosis in abdominal surgery. Thromb Haemost 67 (1992) 627-630
39. Gallus A., Cade J., Ockelford P., et al. Orgaran (Org 10172) or heparin for preventing venous thrombosis after elective surgery for malignant disease? A double-blind, randomised, multicentre comparison. ANZ-Organon Investigators' Group. Thromb Haemost 70 (1993) 562-567
40. Bounameaux H., Huber O., Khabiri E., Schneider P.A., Didier D., and Rohner A. Unexpectedly high rate of phlebographic deep venous thrombosis following elective general abdominal surgery among patients given prophylaxis with low-molecular-weight heparin. Arch Surg 128 (1993) 326-328
41. Nurmohamed M.T., Verhaeghe R., Haas S., et al. A comparative trial of a low molecular weight heparin (enoxaparin) versus standard heparin for the prophylaxis of postoperative deep vein thrombosis in general surgery. Am J Surg 169 (1995) 67-71
42. ENOXACAN Study Group. Efficacy and safety of enoxaparin versus unfractionated heparin for prevention of deep vein thrombosis in elective cancer surgery: a double-blind randomized multicentre trial with venographic assessment. ENOXACAN Study Group. Br J Surg 84 (1997) 1099-1103
43. Etchells E., McLeod R.S., Geerts W., Barton P., and Detsky A.S. Economic analysis of low-dose heparin vs the low-molecular-weight heparin enoxaparin for prevention of venous thromboembolism after colorectal surgery. Arch Intern Med 159 (1999) 1221-1228
44. Bergqvist D., Burmark U., Flordal P., et al. Low molecular weight heparin started before surgery as prophylaxis against deep vein thrombosis: 2500 versus 5000 Xal units in 2070 patients. Br J Surg 82 (1995) 496-501
45. Agnelli G., Bergqvist D., Cohen A.T., Gallus A., Gent M., and on behalf of the PEGASUS investigators. Randomised clinical trial of postoperative fondaparinux versus perioperative dalteparin for prevention of venous thromboembolism in high risk abdominal surgery. Br J Surg 92 (2005) 1212-1220
46. Turpie A.G., Bauer K., Caprini J., Comp P., Gent M., and Muntz J. Fondaparinux combined with intermittent pneumatic compression (IPC) versus IPC alone in the prevention of VTE after major abdominal surgery: results of the APOLLO study. J Thromb Haemost 3 Suppl. 1 (2005) Abstract number: P1046
47. Bergqvist D., and Lindblad B. A 30-year survey of pulmonary embolism verified at autopsy: an analysis of 1274 surgical patients. Br J Surg 72 (1985) 105-108
48. Lindblad B., Sternby N.H., and Bergqvist D. Incidence of venous thromboembolism verified by necropsy over 30 years. BMJ 302 (1991) 709-711
49. Rasmussen M.S., Wille-Jorgensen P., and Jorgensen L.N. Postoperative fatal pulmonary embolism in a general surgical department. Am J Surg 169 2 (1995) 214-216
50. Lausen I., Jensen R., Jorgensen L.N., et al. Incidence and prevention of deep venous thrombosis occurring late after general surgery: randomised controlled study of prolonged thromboprophylaxis. Eur J Surg 164 (1998) 657-663
51. Bergqvist D., Agnelli G., Cohen A., et al. Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer. N Engl J Med 346 (2002) 975-980
52. Rasmussen M., Jorgensen L., Wille-Jorgensen P., et al. Prolonged prophylaxis with dalteparin after major abdominal surgery. Thromb Haemost (2001) Abstract OC1733
53. Prandoni P., Piccioli A., and Girolami A. Cancer and venous thromboembolism: an overview. Haematologica 84 (1999) 437-445
54. Green D., Hull R., Brant R., and Pineo G. Lower mortality in cancer patients treated with low-molecular-weight versus standard heparin (Letter). Lancet 339 (1992) 1476
55. Siragusa S., Cosmi B., Piovella F., Hirsh J., and Ginsberg J. Low-molecular-weight heparins and unfractionated heparin in the treatment of patients with acute venous thromboembolism: results of a meta-analysis. Am J Med 100 (1996) 269-277
56. von Tempelhoff G.-F., Harenberg J., Niemann F., Hommel G., Kirkpatrick C., and Heilmann L. Effect of low molecular weight heparin (certoparin) versus unfractionated heparin on cancer survival following breast and pelvic cancer surgery: a prospective randomized double-blind trial. Int J Oncol 16 (2000) 815-824
57. Zacharski L., Ornstein D., and Mamourian A. Low-molecular-weight heparin and cancer. Semin Thromb Hemost 26 (2000) 69-77
58. Cosgrove R.H., Zacharski L.R., Racine E., and Andersen J.C. Improved cancer mortality with low-molecular-weight heparin treatment: a review of the evidence. Semin Thromb Hemost 28 (2002) 79-87
59. Kakkar AK, Kadziola Z, Williamson MN, Levine MN, Low V, Lemione NR. Low molecular weight heparin (LMWH) therapy and survival in advanced cancer. In: Presented at the 44th annual meeting of the American Society of Hematology 6-10 December 2002. 2002. Abstract 557.